214
Participants
Start Date
August 11, 2018
Primary Completion Date
May 27, 2020
Study Completion Date
May 27, 2020
Trastuzumab
An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks
Pertuzumab
An initial dose of 840 mg, followed by 420 mg every 3-weeks
Carboplatin
A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks
Docetaxel
75 mg/m2 every 3-weeks
Besat Clinic, Rasht
Dr. Behrouz Najafi's office, Rasht
Dr. Mehdi Mirblouk's office, Rasht
Razi Hospital, Rasht
Dr. Aboulqasem Allahyari's office, Mashhad
Imam Reza Hospital, Mashhad
Qaem Hospital, Mashhad
Sanabad Hospital, Mashhad
Arvand Hospital, Ahvāz
Baqaei Hospital, Ahvāz
Shafa Hospital, Ahvāz
Milad Hospital, Isfahan
Saba Clinic, Isfahan
Seyed-Al-Shohada Hospital, Isfahan
Sheikh Mofid Clinic, Isfahan
Dr. Behjat Kalantari's office, Kerman
Javad-Al-Aemeh Clinic, Kerman
Shahid Bahonar Hospital, Kerman
Dr. Mehrdad Payende's office, Kermanshah
Amir Hospital, Shiraz
Namazi Hospital, Shiraz
Shahid Faghihi Hospital, Shiraz
Shams Hospital, Tabriz
Baqiatallah Hospital, Tehran
BuoAli Hospital, Tehran
Dr. Safa Najjar Najafi's office, Tehran
Ebn-Sina Hospital, Tehran
Firoozgar Hospital, Tehran
Imam Khomeini Hospital, Tehran
Iran-Mehr Hospital, Tehran
Jam Hospital, Tehran
Jihad University Clinic, Tehran
Masih Daneshvari Hospital, Tehran
Massoud Clinic, Tehran
Mehrad Hospital, Tehran
Naft Hospital, Tehran
Rasool Akram Hospital, Tehran
Resalat Hospital, Tehran
Sajjad Hospital, Tehran
Sina Hospital, Tehran
Taleghani Hospital, Tehran
Tehran Hospital, Tehran
Toos Hospital, Tehran
Dr.Mortazavizadeh's office, Yazd
Lead Sponsor
Cinnagen
INDUSTRY